ProMIS Neurosciences Inc. Common Shares (ON) (PMN) Stock Price

PMNStock

$8.15−30.64%52W

Market Cap$73.09M

P/E—

PEG Ratio—

Div yield—

Beta-0.34

PMN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-42.27%

Price vs S&P 500 (4W)-38.88%

VGM Score32.02

Book Value / Share (Quarterly)$5.51

P/TBV (Annual)5.79x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-4.70

Price vs S&P 500 (YTD)7.40%

Net Profit Margin (TTM)-12900.00%

EPS (TTM)$-12.61

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-12.61

EPS (Annual)$-1.07

ROI (Annual)-352.02%

Net Profit Margin (5Y Avg)-12306.41%

Cash / Share (Quarterly)$5.96

ROA (Last FY)-97.01%

EBITD / Share (TTM)$-8.60

ROE (5Y Avg)-725.53%

Operating Margin (TTM)-12900.00%

Cash Flow / Share (Annual)$-13.06

P/B Ratio1.48x

P/B Ratio (Quarterly)2.39x

Net Income / Employee (Annual)$-2,202,100

Net Interest Coverage (TTM)-5.53x

ROA (TTM)-109.15%

EPS Incl Extra (Annual)$-1.07

Current Ratio (Annual)0.88x

Quick Ratio (Quarterly)7.44x

3-Month Avg Trading Volume0.07M

52-Week Price Return-30.64%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.20

P/S Ratio (Annual)7308.67x

Asset Turnover (Annual)0.01x

52-Week High$27.40

Operating Margin (5Y Avg)-12266.41%

EPS Excl Extra (Annual)$-1.07

26-Week Price Return-32.37%

Quick Ratio (Annual)0.60x

13-Week Price Return-46.35%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.85x

Enterprise Value$19.66M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-46400.00%

Cash / Share (Annual)$2.86

3-Month Return Std Dev93.76%

Net Income / Employee (TTM)$-7,038,000

ROE (Last FY)-352.02%

EPS Basic Excl Extra (Annual)$-1.07

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-12.61

Receivables Turnover (Annual)0.29x

ROI (TTM)-79.35%

P/S Ratio (TTM)7308.67x

Pretax Margin (5Y Avg)-12306.41%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$4.97

Price vs S&P 500 (52W)-46.17%

Year-to-Date Return19.33%

5-Day Price Return-13.76%

EPS Normalized (Annual)$-1.07

ROA (5Y Avg)-229.81%

Net Profit Margin (Annual)-46400.00%

Month-to-Date Return-24.88%

Cash Flow / Share (TTM)$-1.78

EBITD / Share (Annual)$-1.16

Operating Margin (Annual)-46300.00%

LT Debt / Equity (Annual)0.69x

ROI (5Y Avg)-711.40%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-12.61

P/TBV (Quarterly)5.79x

P/B Ratio (Annual)1.88x

Pretax Margin (TTM)-12900.00%

Book Value / Share (Annual)$12.61

Price vs S&P 500 (13W)-49.03%

Beta-0.34x

Revenue / Share (TTM)$0.00

ROE (TTM)-79.35%

52-Week Low$6.27

mGradeD

vgmGradeD

PMN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$1.90	-$1.78	+6.18%(+$0.12)
Q4 2025	Mar 25, 2026	-$6.71	-$30.05	-348.09%(-$23.34)
Q3 2025	Nov 12, 2025	-$9.99	-$8.40	+15.87%(+$1.59)
Q2 2025	Aug 13, 2025	-$6.04	-$9.98	-65.33%(-$3.94)

PMN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.11

4.10

4.08

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PMNProMIS Neurosciences Inc. Common Shares (ON)	—	—	D	7308.7x	—	—	—	$8.15
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About ProMIS Neurosciences Inc. Common Shares (ON)

ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics for neurodegenerative diseases, including Alzheimer's disease, ALS, and multiple system atrophy. The company uses its proprietary ProMIS platform to identify and target toxic misfolded proteins that drive neurodegeneration.

PMN Next Earnings Report

Report dateNov 13, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$1.82

Revenue estimate$0

Also reporting on Nov 13, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

PMN Insider Transactions

BuyAug 5, 2026
KAPLAN JOHANNE
Officer
Shares: 2,280Value: $30,324

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

ARQArq, Inc. Common StockIndustrial Chemicals
FSIFlexible Solutions International, Inc.Industrial Chemicals
PTHSPelthos Therapeutics Inc.Biological Products
OKYOOKYO Pharma Limited Ordinary SharesBiological Products
CRDFCardiff Oncology, Inc. Common StockBiological Products
CGTXCognition Therapeutics, Inc. Common StockBiological Products
CSBRChampions Oncology, Inc.Biological Products
SLSNSolesence, Inc. Common StockCosmetics & Toiletries

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$6.27

High$27.40